Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity

• Status: Recruiting
• Trial end date: 2025-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Patients with sleep apnea are at increased risk of developing cardiovascular disease - with women at potentially greater risk than men. Contributing mechanisms are not well understood, but may be related to how women respond to low oxygen and, given over 70% of patients with sleep apnea are obese, the impact of obesity. This project seeks to increase our understanding of mechanisms that may contribute to sex differences in the cardiovascular response to low oxygen with the hope that this knowledge will improve the efficacy of current therapies and support the discovery of novel therapeutics.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Missouri-Columbia
• Treatments: Dexmedetomidine; Norepinephrine; Oxymetazoline; Phentolamine; Phenylephrine

Criteria

Inclusion Criteria:

• 18-45 years of age (premenopausal)

• Healthy weight (BMI ≥18 and ≤25 kg/m2)

• Obese (BMI ≥30 kg/m2)

Exclusion Criteria:

• Pregnancy, breastfeeding, oral hormonal contraceptive use

• Diagnosed sleep apnea or Oxygen desaturation index >10 events/hr

• Current smoking/Nicotine use

• Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy

• Nerve/neurologic disease

• Cardiovascular, hepatic, renal, respiratory disease

• Blood pressure ≥140/90 mmHg

• Diabetes, Polycystic ovarian syndrome

• Communication barriers

• Prescription medications, Sensitivity to lidocaine